VP of Business Development
About the job
- At least 10 years of experience in business development, sales, or alliance management in pharma, biotech, CROs, or life science platform companies.
- A track record of closing complex deals with large pharmaceutical companies, including master services agreement and statement of work negotiation.
- Experience setting pricing for scientific services or platforms.
- At least 3 years of people-management experience, with willingness to remain hands-on.
- A solid understanding of drug discovery and preclinical development, such as DMPK, toxicology, delivery, or translational science.
- An established network across pharmaceutical and biotechnology research and development.
- Comfort working in a fast-moving, early-stage company.
- Lead discovery, scoping, and proposal calls with scientific, procurement, and executive stakeholders at pharmaceutical and biotechnology companies.
- Own master services agreement and statement of work negotiations through close, working with legal, finance, and scientific teams.
- Lead pricing and deal structuring, from pilot studies to multi-study programs.
- Grow existing accounts into repeat, multi-program relationships.
- Work with the CEO, COO, and Chief Strategy Officer to develop commercial models for data and AI products.
- Represent Revalia at industry conferences and customer meetings.
- Hire, manage, and develop a commercial team as the business grows.
- Establish customer relationship management systems, pipeline reviews, forecasting, and contract templates.
- Own the bookings plan and report pipeline and forecast to leadership and the board.
- Work with science, operations, and product teams on feasibility, capacity, and customer feedback.
- Close the most advanced master services agreements and statements of work in the current pipeline.
- Finalize and roll out study pricing.
- Convert early customers into multi-study programs.
- Make the first commercial hires.
- Sign the first customers for discovery data sets.
- Advanced degree: PhD, PharmD, MD, or MBA.
- Experience with new approach methodologies, organ-on-chip, organoids, or human tissue models.
- Experience with data or AI licensing, or milestone- and royalty-based deals.
- Prior commercial leadership at a venture-backed company.
About the company
Revalia Bio uses an ex vivo human organ research platform to provide contract research services for the biopharmaceutical industry. The platform lets researchers study human organs outside the body in a controlled setting, enabling evaluation of drug targets, optimization of lead compounds, and preclinical development across diseases like cancer, cardiovascular, and infectious diseases. Unlike traditional models that rely on non-human systems, Revalia Bio focuses on human organ tissue to generate data that can faster inform drug development. The company differentiates itself through its specialized ex vivo organ platform and services (target validation, lead optimization, preclinical studies) offered as contract research. Its goal is to shorten the drug development timeline and reduce costs by providing human-organ–based testing to pharmaceutical and biotech clients.
Company Size
11-50
Company Stage
Seed
Total Funding
$14.5M
Headquarters
New Haven, Connecticut
Founded
2022
Get referred to Revalia Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 2026 brought ex-Lilly and Verily CEO Casimir Starsiak to scale partnerships.
- FDA's 2025 animal-testing rollback accelerates adoption of human-data preclinical tools.
- Two top-10 pharma customers and revenue quadrupling since 2023 signal early market fit.
What critics are saying
- Revalia still depends on scarce non-transplantable organs and OPO consent workflows.
- Commercial traction remains thin; 2025 revenue was $5.9 million, mostly pilots.
- Altis Labs, Emulate, and organoid platforms compete for the same pharma budgets.
What makes Revalia Bio unique
- Revalia's donated-human-organ perfusion data beats animal models on physiological relevance.
- ARPA-H's $26.7 million CATALYST award validates Revalia's Human Data Trials platform.
- Ex vivo organs and organ-on-chip multimodal datasets create a harder-to-replicate research moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Flexible Work Hours
- Health Insurance
- Dental Insurance
- Vision Insurance
- Disability Insurance
- Wellness Program
- Paid Sick Leave
- Paid Vacation